207 related articles for article (PubMed ID: 20200513)
1. Therapeutic protein-drug interactions and implications for drug development.
Huang SM; Zhao H; Lee JI; Reynolds K; Zhang L; Temple R; Lesko LJ
Clin Pharmacol Ther; 2010 Apr; 87(4):497-503. PubMed ID: 20200513
[TBL] [Abstract][Full Text] [Related]
2. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
Huang SM; Strong JM; Zhang L; Reynolds KS; Nallani S; Temple R; Abraham S; Habet SA; Baweja RK; Burckart GJ; Chung S; Colangelo P; Frucht D; Green MD; Hepp P; Karnaukhova E; Ko HS; Lee JI; Marroum PJ; Norden JM; Qiu W; Rahman A; Sobel S; Stifano T; Thummel K; Wei XX; Yasuda S; Zheng JH; Zhao H; Lesko LJ
J Clin Pharmacol; 2008 Jun; 48(6):662-70. PubMed ID: 18378963
[TBL] [Abstract][Full Text] [Related]
3. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
Huang SM; Temple R; Throckmorton DC; Lesko LJ
Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
[TBL] [Abstract][Full Text] [Related]
4. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.
Zhang L; Xu N; Xiao S; Arya V; Zhao P; Lesko LJ; Huang SM
J Clin Pharmacol; 2012 Jan; 52(1 Suppl):79S-90S. PubMed ID: 22232757
[TBL] [Abstract][Full Text] [Related]
5. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.
Huang SM; Temple R; Xiao S; Zhang L; Lesko LJ
Clin Pharmacol Ther; 2009 Nov; 86(5):475-9. PubMed ID: 19844224
[TBL] [Abstract][Full Text] [Related]
6. Drug interactions evaluation: an integrated part of risk assessment of therapeutics.
Zhang L; Reynolds KS; Zhao P; Huang SM
Toxicol Appl Pharmacol; 2010 Mar; 243(2):134-45. PubMed ID: 20045016
[TBL] [Abstract][Full Text] [Related]
7. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
8. Strategies to assess the drug interaction potential in translational medicine.
Persiani S; Larger P
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):675-86. PubMed ID: 17014388
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown.
Alfaro CL
Psychopharmacol Bull; 2001; 35(4):80-93. PubMed ID: 12397858
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes supporting anticancer product approvals.
Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
[TBL] [Abstract][Full Text] [Related]
11. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
Sudsakorn S; Bahadduri P; Fretland J; Lu C
Curr Drug Metab; 2020; 21(6):403-426. PubMed ID: 32562522
[TBL] [Abstract][Full Text] [Related]
12. Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels.
Basch E
Value Health; 2012 May; 15(3):401-3. PubMed ID: 22583448
[No Abstract] [Full Text] [Related]
13. Draft guidance for industry on developing medical imaging drugs and biologics; availability--FDA. Availability of guidance.
Fed Regist; 1998 Oct; 63(198):55067-9. PubMed ID: 10185833
[TBL] [Abstract][Full Text] [Related]
14. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
Chuang-Stein C; Beltangady M
J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
[TBL] [Abstract][Full Text] [Related]
15. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective.
Chu V; Einolf HJ; Evers R; Kumar G; Moore D; Ripp S; Silva J; Sinha V; Sinz M; Skerjanec A
Drug Metab Dispos; 2009 Jul; 37(7):1339-54. PubMed ID: 19389860
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
Bottomley A; Jones D; Claassens L
Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
[TBL] [Abstract][Full Text] [Related]
18. Radiological health; evaluation of radiation exposure in diagnostic radiology examinations; availability of draft recommendations--FDA. Notice.
Fed Regist; 1983 Jul; 48(147):34520-1. PubMed ID: 10261489
[TBL] [Abstract][Full Text] [Related]
19. "Cocktail" approaches and strategies in drug development: valuable tool or flawed science?
Zhou H; Tong Z; McLeod JF
J Clin Pharmacol; 2004 Feb; 44(2):120-34. PubMed ID: 14747420
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
